Geron Corporation
NASDAQ:GERN · NASDAQ Global Select
+$0.05 today
Vol 19.57M · Avg 16.28M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$85.8M +50.9% | -$174.6M +5.2% | -$184.1M -29.8% | -$141.9M -22.2% | -$116.1M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.2M -1.4% | $1.2M +18.2% | $1.0M +19.0% | $868.0K +10.9% | $783.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $191.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $88.0K -99.7% | $31.3M +61.8% | $19.4M +141.9% | $8.0M -1.0% | $8.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$68.5M -0.2% | -$68.4M -1229.1% | $6.1M +20.5% | $5.0M -52.2% | $10.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$377.0K +99.0% | -$36.9M -2576.0% | $1.5M +207.9% | -$1.4M -32.7% | -$1.0M | $592.6M | $1.3B | $626.2M |
| Inventory | -$77.9M -105.2% | -$38.0M | $0 -100.0% | $1.4M +32.7% | $1.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $2.7M +9.3% | $2.4M +160.4% | -$4.0M -215.0% | $3.5M +1609.9% | -$232.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $7.1M +76.8% | $4.0M -53.3% | $8.6M +464.2% | $1.5M -85.8% | $10.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $42.0M +613.6% | -$8.2M +18.7% | -$10.1M -1707.3% | $626.0K -36.4% | $984.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$111.0M +49.2% | -$218.6M -30.3% | -$167.7M -31.7% | -$127.4M -33.3% | -$95.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$49.0K +92.8% | -$680.0K +18.1% | -$830.0K -92.6% | -$431.0K -108.2% | -$207.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 -100.0% | $179.5M +14657.3% | -$1.2M -177.4% | $1.6M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$304.4M +36.2% | -$476.9M -0.3% | -$475.6M -84.3% | -$258.0M -45.4% | -$177.4M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $411.7M +10.8% | $371.6M +25.5% | $296.1M -7.6% | $320.5M +28.4% | $249.6M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 +100.0% | -$179.5M -14657.3% | $1.2M +177.4% | -$1.6M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $107.2M +201.2% | -$106.0M +41.2% | -$180.3M -390.5% | $62.1M -13.7% | $71.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 -100.0% | $34.6M +16.4% | $29.7M | $0 -100.0% | $24.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.3M -98.4% | $140.7M -34.0% | $213.3M +205.1% | $69.9M +243.0% | $20.4M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $159.1M +33.7% | $119.0M +585.9% | $17.3M +429.5% | $3.3M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $2.3M -99.3% | $334.4M -7.6% | $362.0M +314.9% | $87.3M +79.7% | $48.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $87.0K +825.0% | -$12.0K +55.6% | -$27.0K -222.7% | $22.0K | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$1.4M -114.7% | $9.7M -30.1% | $13.9M -36.6% | $22.0M -11.9% | $24.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$111.1M +49.3% | -$219.3M -30.1% | -$168.6M -31.9% | -$127.8M -33.5% | -$95.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.53B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.49B
Savara Inc.
NASDAQ:SVRA
$1.11B
Replimune Group, Inc.
NASDAQ:REPL
$839.76M
Valneva SE
NASDAQ:VALN
$507.30M
Rezolute, Inc.
NASDAQ:RZLT
$488.68M
Arvinas, Inc.
NASDAQ:ARVN
$486.89M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$183.95M
SEC Filings
Recent regulatory filings
No filings found.
Does GERN generate free cash flow?
Geron Corporation (GERN) generated -$111,086,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does GERN produce?
Operating cash flow was -$111,037,000.00, before capital expenditures of $49,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.